COMMUNIQUÉS West-GlobeNewswire

IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma
09/07/2026
First peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant Immunotherapy or DRI) clinical results in newly diagnosed glioblastoma Repeat-dose patients achieved median [...]
SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers
09/07/2026
Commercial availability expected in August as the Company advances the rollout of the highest-dose FDA-approved naloxone hydrochloride nasal spray U.S. naloxone market totals ~$144 million in annual sales and ~9.8 [...]
Tris Pharma Launches Adneuris Therapeutics to Advance a New Era in Pain Medicine
09/07/2026
Tris Pharma’s Wholly-Owned Subsidiary is Advancing the Development of Cebranopadol as it Prepares for New Drug Application (NDA) Submission Later This Year MONMOUTH JUNCTION, N.J., July 09, 2026 (GLOBE NEWSWIRE) -- [...]
Fangzhou Named to KPMG China Healthcare 50 for AI-Powered Chronic Disease Care
09/07/2026
SHANGHAI, July 09, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, has been named to the KPMG China Healthcare 50 list, [...]
Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results
09/07/2026
Cohort 1 Topline Data Expected in the Second Week of September 2026 RESEARCH TRIANGLE PARK, N.C., July 09, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company”, “Opus Genetics” or “Opus”), a [...]
Stereotaxis Completes Acquisition of Robocath
09/07/2026
ST. LOUIS and ROUEN, France, July 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has [...]
Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01
09/07/2026
STAFFORD, Texas, July 09, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
New Data at SCCT 2026 Reinforce Heartflow Plaque Analysis as the Standard for AI-Powered Coronary Artery Disease Management
09/07/2026
Heartflow Plaque Staging TM , the only staging tool based on total plaque volume * , is now included with every Heartflow Plaque Analysis Data from over 36,000 patients validate the accuracy, reproducibility and utility [...]
Cytosurge’s CellEDIT Conquers "Impossible" Genome Engineering Challenges
09/07/2026
A new peer-reviewed study validates CellEDIT’s ability to overcome cell-editing barriers, uncovering dermokine’s pivotal role in wound healing and skin cancer biology. Zurich, Switzerland – July 9, 2026 – Cytosurge AG, [...]
NTG Nordic Transport Group A/S - H1 2026 Conference Call
09/07/2026
NTG Nordic Transport Group A/S – H1 2026 Conference Call We expect to release the H1 2026 interim results of NTG Nordic Transport Group on the evening of August 10, 2026. A webcast and conference call will be held in [...]
New German expert consensus provides first risk-based recommendations for sNPWT use in closed surgical incisions
09/07/2026
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, today announces the publication of new consensus-based guidance - developed independently by expert clinicians for the use of single-use negative [...]
Roche receives CE Mark for blood test to identify tuberculosis infection
09/07/2026
The Elecsys IGRA TB test expands global access to tuberculosis infection testing, advancing progress toward the World Health Organization's elimination targets. Performed on Roche’s industry-leading and widely available [...]
Dysport® est la première toxine botulinique à obtenir des résultats préliminaires positifs de phase III, à la fois dans la migraine épisodique et dans la migraine chronique.
09/07/2026
Dysport ® a obtenu des résultats préliminaires statistiquement significatifs de phase III, atteignant les critères d’évaluation principaux dans la migraine épisodique (E-BEOND) et dans la migraine chronique (C-BEOND) [...]
Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine.
09/07/2026
Dysport ® achieved statistically significant topline Phase III results, meeting primary endpoints in both episodic (E-BEOND) and chronic (C-BEOND) migraine Dysport is the first botulinum toxin in episodic migraine to [...]
New German expert consensus highlights role for NPWT in mitigating the economic impact of postoperative wound complications
09/07/2026
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, today announces the publication by expert clinicians of new consensus-based guidance - developed by them for the use of single-use negative [...]
Outliyr's Independent Spectrometer Tests Find Popular Red Light Therapy Devices Delivering From 67 Percent to Nearly Triple Their Advertised Power
09/07/2026
Outliyr's free public database catalogs more than seventy red light therapy panels and other light therapy devices, and publishes its own spectrometer measurements next to manufacturer claims for the units it has tested [...]
Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity
08/07/2026
BOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine [...]
Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101
08/07/2026
IRX-101 targets a significant need for millions of patients facing vision loss and has the potential to improve the standard of care Positive Phase 2b/3 data and an FDA-aligned Phase 3 program provide a clear and near- [...]
BrightSpring Health Services, Inc. to Announce Second Quarter 2026 Financial Results on July 31, 2026
08/07/2026
LOUISVILLE, Ky., July 08, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG) announced today that it plans to release its second quarter 2026 financial results [...]

Pages